ADVANCED UROTHELIAL CARCINOMA
Clinical trials for ADVANCED UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug shows promise for Hard-to-Treat bladder cancers
Disease control OngoingThis study tests a drug called olaparib in 60 people with advanced bladder or related cancers that have specific DNA repair defects. Olaparib blocks a protein that cancer cells need to fix their DNA, which may stop the cancer from growing. The goal is to see if the drug can shrin…
Matched conditions: ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…
Matched conditions: ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New targeted drug aims to fight hard-to-treat bladder cancers
Disease control OngoingThis study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…
Matched conditions: ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug combo aims to shrink Hard-to-Treat cancers
Disease control OngoingThis phase 2a trial tests a new form of the chemotherapy drug gemcitabine (FF-10832) given alone or with the immunotherapy pembrolizumab (Keytruda) in 120 adults with advanced bladder or non-small cell lung cancer. The study first checks safety and finds the best dose, then looks…
Matched conditions: ADVANCED UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
Scientists hunt for clues to predict which cancer treatments work best
Knowledge-focused OngoingThis study collects tissue and blood samples from 156 people with advanced prostate, kidney, or bladder cancers. Researchers analyze these samples to find genetic markers that predict how well different treatments will work. Participants do not receive any experimental treatment …
Matched conditions: ADVANCED UROTHELIAL CARCINOMA
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC